Lyme Disease Vaccine Pipeline: VLA15 Phase 3, mRNA & Novel Candidates
Current Landscape
No licensed human Lyme vaccine since LYMErix withdrawal (2002). Multiple platforms in development targeting Borrelia burgdorferi outer surface proteins.
Leading Candidates
| Candidate | Platform | Target | Stage | Developer |
|---|---|---|---|---|
| VLA15 | Recombinant OspA (6 serotypes) | OspA | Phase 3 (VALOR trial, NCT05477524) | Valneva/Pfizer |
| LYMErix-NextGen | Recombinant OspA + novel adjuvant | OspA | Preclinical/Phase 1 | GSK + academic partners |
| OspA-conjugate vaccines | Protein-polysaccharide conjugate | OspA + carrier | Preclinical | Multiple (Yale, CDC, etc.) |
| Multivalent/chimeric | Multi-antigen (OspA, OspC, DbpA, BBK32) | Broad strain coverage | Preclinical/Phase 1 | Various |
| mRNA/saRNA vaccines | Lipid nanoparticle mRNA | OspA, OspC, etc. | Preclinical | Moderna, Pfizer/BioNTech, academic |
| Inactivated whole-cell | Killed B. burgdorferi | Broad antigen repertoire | Preclinical | Multiple |
Key Challenges
- Antigenic diversity across Borrelia genospecies (US vs. Europe).
- Safety signal from LYMErix (autoimmune arthritis concerns—HLA-DR4 linkage).
- Correlates of protection not fully defined.
- Endemic-area trial logistics, cost-effectiveness.
Timeline
VLA15 Phase 3 completion ~2025; potential licensure 2026–2027 if efficacy/safety confirmed. Other platforms 5–10 years away.
Lyme Disease - Related Articles
- Tracking Lyme Disease Treatment Progress: What to Expect
- Garlic and Lyme Disease: Exploring Natural Support
- Lyme Disease Treatment: Exploring Homeopathic Approaches
- Pap Smear and the Hymen: Does It Break the Hymen?
- Borrelial Lymphocytoma: Understanding Lyme Disease Complications
- Understanding Lyme Disease: Symptoms, Effects & Impacts
- Scalp Ringworm Healing: Signs of Improvement and Follow-Up
